Dopamine agonist-resistant prolactinomas: A review

Journal of Neurosurgery

Volumn 114, Issue 5, 2011, Pages 1369-1379

  Oh, Michael C ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine agonist; Dopamine agonist resistance; Pituitary adenoma; Prolactinoma

Indexed keywords

ADENYLATE CYCLASE; BROMOCRIPTINE; CABERGOLINE; CD31 ANTIGEN; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PERGOLIDE MESILATE; PROLACTIN; PROTEIN G; QUINAGOLIDE; RALOXIFENE; SOMATOSTATIN; TEMOZOLOMIDE;

AMENORRHEA; ANGIOGENESIS; CANCER INVASION; CARCINOMA; DOPAMINE AGONIST RESISTANT PROLACTINOMA; DRUG MEGADOSE; DRUG RESPONSE; GALACTORRHEA; GAMMA KNIFE RADIOSURGERY; GYNECOMASTIA; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPITUITARISM; INFERTILITY; LIBIDO; META ANALYSIS (TOPIC); NERVE COMPRESSION; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; RADIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; TRANSSPHENOIDAL SURGERY; TUMOR GROWTH; VASCULARIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; DACARBAZINE; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MITOTIC INDEX; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RECEPTORS, ESTROGEN; SEX FACTORS;

EID: 79955671913     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2010.11.JNS101369     Document Type: Review

References (83)

1. Bassetti M, Spada A, Pezzo G, Giannattasio G: Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 58: 268-273, 1984
2. Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP, et al: Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary [epub ahead of print], 2009
3. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338-2343, 1996
4. Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J, et al: Dopaminergic receptors in human prolactin- secreting adenomas: a quantitative study. J Clin Endocrinol Metab 51:1037-1044, 1980
5. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, et al: Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 74:577-584, 1992
6. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P: Prolactinomas and resistance to dopamine agonists. Horm Res 38: 84-89, 1992
7. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, et al: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322, 1994
8. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A: Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol 8:737-746, 1996
9. Cannavò S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F: Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 22: 306-309, 1999
10. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273, 2006
11. Colao A: Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575-596, 2009
12. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579, 1997
13. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G: Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787-800, 2002
14. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883, 1997
15. Colao A, Lombardi G: Growth-hormone and prolactin excess. Lancet 352:1455-1461, 1998
16. Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G: Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 10:111-123, 2009
17. Cronin MJ, Cheung CY, Wilson CB, Jaffe RB, Weiner RI: [3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. J Clin Endocrinol Metab 50: 387-391, 1980
18. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775, 2006
19. De Camilli P, Macconi D, Spada A: Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278:252-254, 1979
20. Delgrange E, Crabbé J, Donckier J: Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 49:250-253, 1998
21. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D: Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747-752, 2009
22. Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J: Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147:751-758, 2005
23. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J: Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107, 1997
24. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261, 2001
25. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM: Effect of the new dopaminergic agonist CV 205- 502 on plasma prolactin levels and tumour size in bromocriptine- resistant prolactinomas. Clin Endocrinol (Oxf) 34:25-29, 1991
26. Faria MA Jr, Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg 56:33-43, 1982
27. Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, et al: Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155:823-829, 2006
28. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, et al: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46:409-413, 1997
29. Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, et al: Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 8:357-363, 2008
30. Fiorentini C, Guerra N, Facchetti M, Finardi A, Tiberio L, Schiaffonati L, et al: Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Mol Endocrinol 16:353-366, 2002
31. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, et al: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 158:595-603, 2008
32. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 27:485-534, 2006
33. Gürlek A, Karavitaki N, Ansorge O, Wass JA: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143-153, 2007
34. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M: Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631-637, 2009
35. Hamilton DK, Vance ML, Boulos PT, Laws ER: Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8:53-60, 2005
36. Hardy J, Beauregard H, Robert F: Prolactin-secreting pituitary adenomas: transsphenoidal microsurgical treatment. Clin Neurosurg 27:38-47, 1980
37. Heiman ML, Ben-Jonathan N: Rat anterior pituitary dopaminergic receptors are regulated by estradiol and during lactation. Endocrinology 111:1057-1060, 1982
38. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, et al: Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268-3276, 1999
39. Kansra S, Chen S, Bangaru ML, Sneade L, Dunckley JA, Ben- Jonathan N: Selective estrogen receptor down-regulator and selective estrogen receptor modulators differentially regulate lactotroph proliferation. PLoS ONE 5:e10060, 2010
40. Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER: Estrogen receptors in prolactinomas: a clinicopathological study. Pituitary 1:91-98, 1999
41. Kitano M, Taneda M, Shimono T, Nakao Y: Extended transsphenoidal approach for surgical management of pituitary adenomas invading the cavernous sinus. J Neurosurg 108:26-36, 2008
42. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, et al: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185-189, 2007
43. Lamberts SW, de Quijada M, Klijn JG: The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest 3:343-347, 1980
44. Lamberts SW, Verleun T, Oosterom R: Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 34:339-342, 1982
45. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M: Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87: 3180-3186, 2002
46. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
47. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AM, Ballarino C, Stalldecker G, et al: Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol 20:35-40, 2009
48. Maurer RA: Estradiol regulates the transcription of the prolactin gene. J Biol Chem 257:2133-2136, 1982
49. Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, et al: Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 8:175-181, 1994
50. Molitch ME: The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 93:4643-4645, 2008
51. Molitch ME: Dopamine resistance of prolactinomas. Pituitary 6:19-27, 2003
52. Molitch ME: Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55-65, 2002
53. Molitch ME: Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52, 2005
54. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, et al: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705, 1985
55. Monson JP: The epidemiology of endocrine tumours. Endocr Relat Cancer 7:29-36, 2000
56. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P: Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 135:413-420, 1996
57. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537-546, 1997
58. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, et al: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10:81-86, 2007
59. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721-4727, 2008
60. Páez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
61. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J: [Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study.] Presse Med 24:753-757, 1995 (Fr)
62. Pasqualini C, Bojda F, Kerdelhué B: Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomized rats. Endocrinology 119:2484-2489, 1986
63. Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD: Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89: 163-170, 2009
64. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509, 1989
65. Pinero A, Marcos-Alberca P, Fortes J: Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976-1977, 2005
66. Pollock BE, Brown PD, Nippoldt TB, Young WF Jr: Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 62:1271-1278, 2008
67. Rohmer V, Freneau E, Morange I, Simonetta C: Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris) 61:411-417, 2000
68. Sheehan J, Rainey J, Nguyen J, Grimsdale R, Han S: Temozolomide- induced inhibition of pituitary adenoma cells. Laboratory investigation. J Neurosurg [epub ahead of print May 14, 2010. DOI: 10.3171/2010.4.JNS1024]
69. Simonis G, Fuhrmann JT, Strasser RH: Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 22:1936-1942, 2007
70. Spinks JJ, Ryan FJ: Cabergoline resistance in pediatric prolactinomas. J Pediatr Hematol Oncol 31:377-379, 2009
71. Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr: Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12:158-164, 2009
72. Thomson JA, Davies DL, McLaren EH, Teasdale GM: Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ 309:1409-1410, 1994
73. Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin- producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178-1183, 1982
74. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA: Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159-1162, 2000
75. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA: Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol 165: 475-481, 2000
76. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44:254-263, 1999
77. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183, 2004
78. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522, 1999
79. Völker W, Gehring WG, Berning R, Schmidt RC, Schneider J, von zur Mühlen A: Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol (Copenh) 101:491-500, 1982
80. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, et al: The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol (Oxf) 39: 323-329, 1993
81. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909, 1994
82. Wood DF, Johnston JM, Johnston DG: Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf) 35:455-466, 1991
83. Zornitzki T, Knobler H, Nass D, Hadani M, Shimon I: Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma. Horm Res 61:111-116, 2004